Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Meloxicam]

J Sternon1, T Appelboom

  • 1CUMG-ULB, Hôpital Erasme, U.L.B.

Revue Medicale De Bruxelles
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Meloxicam, a selective COX-2 inhibitor, matches NSAID efficacy for rheumatic diseases. It offers improved gastrointestinal safety, though its COX-2 selectivity benefits are debated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Effects of Site Preparation for Pine Forest/Switchgrass Intercropping on Water Quality.

Journal of environmental quality·2015
Same author

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Annals of the rheumatic diseases·2013
Same author

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

Clinical and experimental rheumatology·2011
Same author

Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial.

Clinical and experimental rheumatology·2011
Same author

[What is new in interventional rheumatology?].

Revue medicale de Bruxelles·2008
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed.
  • Meloxicam is an oxicam NSAID with preferential inhibition of COX-2 over COX-1.
  • This selectivity aims to reduce gastrointestinal side effects associated with traditional NSAIDs.

Purpose of the Study:

  • To evaluate the efficacy and safety of meloxicam in patients with rheumatic diseases.
  • To compare meloxicam's performance against other NSAIDs.
  • To assess the clinical relevance of meloxicam's COX-2 selectivity.

Main Methods:

  • Clinical trials involving over 5000 patients.
  • Study populations included osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis flares.
  • Comparative analysis with established NSAIDs.

Related Experiment Videos

Main Results:

  • Meloxicam demonstrated comparable efficacy to other NSAIDs in treating rheumatic conditions.
  • Global data analysis revealed superior gastrointestinal tolerance for meloxicam.
  • The clinical significance of its anti-COX-2 selectivity remains a subject of discussion.

Conclusions:

  • Meloxicam is an effective NSAID for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
  • Its improved gastrointestinal safety profile is a key advantage.
  • Further research may be needed to fully elucidate the clinical implications of its COX-2 selectivity.